FRE Firebrick Pharma Ltd
- 0.063
- +0.001+1.61%
Firebrick Pharma Ltd News
Firebrick Pharma Raises AU$800,000 via Placement
Firebrick Pharma (ASX:FRE) received binding commitments for a placement of AU$800,000 from a substantial shareholder, comprising 16 million shares at a discounted price of AU$0.05 apiece, according to
Firebrick Pharma Sees Substantial Holder up Stake to 12% in Placement
Betadine-like nasal spray provider Firebrick Pharma (ASX:FRE) – whose flagship product Nasodine has recently gone live for sale in the US – has raised $0.8M in a placement largely backed by an existing substantial holder.
Firebrick Pharma Appoints Auditor
Firebrick Pharma (ASX:FRE) appointed BDO Audit as company auditor, according to a Monday filing with the Australian bourse. The appointment follows the resignation of BDO Audit (WA) in line with the f
Firebrick Pharma Launches Antiseptic Nasal Spray Into US Online Market
An antiseptic nasal spray developed by Melbourne-based Firebrick Pharma (ASX: FRE) to attack the common cold has been officially launched online for US customers.
Firebrick Pharma's Nasodine Nasal Spray Enters US Market
Firebrick Pharma (ASX:FRE) is launching its Nasodine nasal spray in the US Wednesday, according to a same-day Australian bourse filing. The nasal spray can now be purchased from the company's US websi
Firebrick Pharma Phase 2 Covid-19 Trial Published in Laryngoscope Journal
Firebrick Pharma's (ASX:FRE) phase 2 Covid-19 trial has been published in the Larynggoscope journal, according to a Tuesday Australian bourse filing. Price (AUD): $0.06, Change: $0.00, Percent Change:
Firebrick Pharma Gets Coverage Extension of COVID-19 Patent in US
Firebrick Pharma (ASX:FRE) received a notice of allowance of a second patent relating to COVID-19 in the US. The new patent for its Nasodine nasal spray specifically extended the patent coverage to in
Firebrick Pharma to Release Shares From Escrow; Shares Rise 4%
Firebrick Pharma (ASX:FRE) is set to release 62,732,537 shares from escrow upon their expiry date on Jan. 28, according to a Friday filing. Two directors of the pharmaceutical firm own 30,054,412 shar
Firebrick Pharma Withdraws Appeal Against Regulator's Decision Over Nasodine Nasal Spray
Firebrick Pharma (ASX:FRE) withdrew its appeal with the Administrative Appeals Tribunal against the Therapeutic Goods Administration's decision not to approve Nasodine nasal spray. The pharmaceutical
Firebrick Pharma's Nasodine Nasal Spray COVID-19 Patent Granted in South Africa
Firebrick Pharma (ASX:FRE) said Wednesday that its patent covering the use of Nasodine nasal spray in COVID-19 has now been granted in South Africa. The US and Australia have already granted patents f
Firebrick Pharma Receives AU$1.8 Million R&D Tax Rebate
Firebrick Pharma (ASX:FRE) received a research and development tax incentive of AU$1.8 million for 2022/23. The tax rebate is mainly associated with costs incurred for clinical trials for Nasodine, wh
Firebrick Says Independent Probe Into Nasodine Trial Results Did Not Find Errors
Firebrick Pharma (ASX:FRE) said an independent preliminary investigation into the Phase III trial results of the firm's Nasodine Nasal Spray "has not revealed any systematic error or other data issue"
Firebrick Pharma's Cold Medication Fails Phase III Trial
Firebrick Pharma (ASX:FRE) said trial statisticians have completed their efficacy analysis of the "headline results" in the Phase III trial of firm's Nasodine Nasal Spray, being developed to treat com
Firebrick Pharma Completes Enrollment for Cold Treatment Trial; Shares Soar 17%
Firebrick Pharma (ASX:FRE) completed the enrollment phase for its phase three trial investigating the use of the nasal spray Nasodine as a treatment for the common cold. The study was conducted on 500
Is Firebrick Pharma (ASX:FRE) In A Good Position To Invest In Growth?
Analysis
Price Target
No Data
